We are no longer accepting new Cymbalta withdrawal cases.
Los Angeles, California – On Friday, June 19, 2015, Judge Stephen V. Wilson, U.S. District Court for the Central District of California, Los Angeles, denied Cymbalta manufacturer, Eli Lilly and Company’s motions for summary judgment (seeking to dismiss the cases), and has set the cases for consecutive jury trials beginning on August 4 and August 11, 2015.
The cases allege that Lilly failed to adequately warn the plaintiffs and their physicians of Cymbalta’s true withdrawal risks. These cases, Herrera v. Eli Lilly and Company (case no. 2:13-cv-2702-SVW-MAN) and Hexum v. Eli Lilly and Company (case no. 2:13-cv-2701-SVW-MAN) will be the first Cymbalta withdrawal cases to go to trial in the country. There are hundreds of Cymbalta withdrawal cases on file and thousands in the pipeline.
*Note: Google Chrome users will not be able to see the first or last page because they include images. Please use IE, Firefox or Safari, etc., to view the complete documents.
Cymbalta is a selective serotonin norepinephrine reuptake inhibitor antidepressant, commonly called an “SNRI,” which was first approved by the U.S. Food and Drug Administration for depression in 2004. The drug is also used to treat anxiety, fibromyalgia, pain associated with diabetes and chronic muscle, and bone pain.
A separate United States Federal District Court Judge, the Honorable Anthony J Trenga, Eastern District of Virginia, has set two more Cymbalta withdrawal cases for trial to begin on August 24, 2015, Ali v. Eli Lilly and Company (case no. 1:14-cv-01615-AJT-JFA) and Hagan-Brown v. Eli Lilly and Company (case no. 1:14-cv-01614-AJT-JFA).
Statement by attorney R. Brent Wisner of Baum Hedlund Aristei & Goldman, who argued the motions before Judge Wilson and Judge Trenga: We are pleased with Judge Wilson’s rulings and our clients are looking forward to having their day in court.
Plaintiffs Hexum and Herrera are represented by Michael L. Baum, R. Brent Wisner and Bijan Esfandiari of Baum Hedlund Aristei & Goldman, based in Los Angeles, California and Harris L. Pogust and T. Matthew Leckman of Pogust, Braslow & Millrood, LLC, of Conshohocken, Pennsylvania.
Together, the law firms of Baum Hedlund Aristei & Goldman, Pogust, Braslow & Millrood, LLC, Keller Rohrbach, L.L.P. and Deskin Law Firm, are representing over 2,000 plaintiffs who allege they have suffered an injury, and in some cases, death, due to symptoms suffered while attempting to discontinue Cymbalta.